Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocular Therapeutix, Inc. filings document the formal disclosure record for a Nasdaq-listed biopharmaceutical issuer developing and commercializing ophthalmic therapies. Form 8-K reports furnish operating and financial results, Regulation FD materials and clinical-trial disclosures tied to AXPAXLI in wet age-related macular degeneration, along with material-event reporting on governance matters, executive officer arrangements, material agreements and capital-structure disclosures.
Proxy materials cover shareholder voting matters, executive compensation and equity-award disclosures, including information presented under pay-versus-performance reporting. The filings also identify Ocular Therapeutix common stock, par value $0.0001 per share, as registered on The Nasdaq Global Market under the symbol OCUL.
Ocular Therapeutix, Inc.’s Chief Scientific Officer Jeffrey S. Heier reported an automatic sale of 3,057 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.28 per share to cover tax withholding tied to restricted stock units that vested on February 22, 2026.
The transaction was executed under a durable automatic sale instruction adopted on April 9, 2024, meaning it was not a discretionary trade. After this sale, Heier directly held 323,368 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak reported an automatic sale of 1,759 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.28 per share under a pre-arranged durable automatic sale instruction.
The sale was made to cover tax withholding obligations tied to the vesting of restricted stock units on February 22, 2026, and is described as non-discretionary. After this sell-to-cover transaction, Nayak directly held 330,653 shares of Ocular Therapeutix common stock.
Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open‑market sale of 3,510 shares of common stock at a weighted average price of $7.74 per share on February 20, 2026. The sale was executed under a durable automatic sale instruction adopted on June 1, 2024 to cover tax withholding from restricted stock units that vested on February 11, 2026, and is described as non‑discretionary. Following this transaction, Waheed beneficially owns 314,907 shares of Ocular Therapeutix common stock.
Ocular Therapeutix director Richard L. Lindstrom, MD, bought shares of the company’s common stock in the open market. On this transaction date, he purchased 60,229 shares at a weighted average price of $7.66 per share, bringing his directly held stake to 246,933 shares.
OCUL submitted a notice to sell 2,810 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/22/2026.
Shares outstanding were 217,691,779 as of 02/23/2026. The excerpt also shows a prior sale of 3,007 common shares on 11/24/2025 for $36,150.15.
Oculus Therapeutics (OCUL) reported proposed sales of common stock via a Form 144 notice tied to restricted shares vesting under a registered plan on 02/22/2026.
The filing names Pravin Dugel and lists prior sales of 124,882 shares on 02/12/2026 for $1,128,583.61 and 19,530 shares on 11/24/2025 for $235,082.61.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a notice regarding the proposed sale of 3,057 common shares tied to restricted stock vesting under a registered plan, dated 02/22/2026. The filing lists that the sale method is by the Issuer.
The excerpt also shows a prior sale by Jeffrey S. Heier of 3,469 common shares on 11/24/2025, with a numeric value 41,771.96 recorded alongside that transaction.
OCUL notice of a proposed sale of 1,759 common shares tied to restricted stock vesting under a registered plan on 02/22/2026.
The filing also records prior sales by Sanjay Nayak of 10,348 shares on 02/12/2026 and 1,878 shares on 11/24/2025.
Nadia K. Waheed submitted a Form 144 reporting a proposed sale of 3,510 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/11/2026. The filing also shows 7,863 shares were sold on 02/12/2026.
Ocular Therapeutix Chief Operating Officer Donald Notman reported an automatic open-market sale of 11,446 shares of common stock at a weighted average price of $9.04 per share on February 12, 2026. The sale was executed under a durable automatic sale instruction to satisfy tax withholding obligations tied to restricted stock units that vested on February 11, 2026, and was not a discretionary trade. Following this transaction, Notman directly owns 366,356 shares of Ocular Therapeutix common stock.